Spektron Systems has actively engaged in developing synthesis and test plans on five representative molecules representing designs for an antipsychotic medication. Primarily for the purposes of estimating testing costs at a detailed level, our approach is to select key in vitro and in vivo/behavioral tests that we can or have modeled already in silico. These will include tests for pharmacokinetics, a toxicity (e.g. hERG inhibition), and a behavioral efficacy test such as Locomotor Activity or Pre-Pulse Inhibition. These are key to approaching a pre-IND conference with the Food and Drug
